A deep scientific anchorage with first-class international academic research
As a spin-off of French academic research, ILTOO Pharma built a robust public-private partnership with APHP (“Assistance Publique des Hôpitaux de Paris”) and Sorbonne University. Our scientific excellence and disruptive therapeutic approach were recognized through the award of multi-million euros of R&D grants at national and international levels.
ILTOO Pharma is involved in DIABIL-2 project, an EU-funded program including a phase 2 clinical trial in patients with type 1 diabetes gathering 5 partners across Europe (www.diabil-2.eu) including Basel university (Switzerland) and Leiden University Medical Center (Netherlands).
ILTOO Pharma takes part in iMAP project, the first-prize winner of the 2nd edition of French “Réseau Hospitalo-Universitaire” (RHU) call for proposal supervised by “Agence National pour la Recherche”.
Active strategy of industrial partnership
Industrial partnership is a key component of ILTOO Pharma’s corporate development strategy. ILTOO is thus continuously and actively exploring potential out-licensing opportunities to foster the development of its R&D pipeline.